Graphy launches 'Graphy SMA Times' newsletter to engage global medical professionals

Graphy, the South Korean dental aligner and 3D printing company led by CEO Shim Woon-seop, launched its official newsletter 'Graphy SMA Times: Global Insight' on April 20, 2026. The newsletter is published in both Korean and English editions and is structured around four core sections: Science & Evidence, Clinical Excellence, Tech & Support, and Inside Graphy. Each section is designed to deliver peer-reviewed research summaries, before-and-after clinical case studies, frequently asked technical support questions, and corporate updates, respectively. The company positions the newsletter not as a marketing channel but as a global communication platform to continuously demonstrate the clinical value of its Shape Memory Aligner (SMA) technology.

This move is significant because it reflects Graphy's strategic push to build a direct, recurring engagement channel with the global orthodontic and dental professional community, rather than relying solely on trade shows or distributor relationships. In the context of the medical-dental vertical, where clinical evidence and peer validation are critical for adoption, a structured content platform that links research directly to clinical application can serve as a powerful trust-building tool. Graphy's SMA technology, which leverages shape-memory polymers for clear aligner therapy, competes directly with established players like Align Technology (Invisalign) and a growing field of Asian competitors. By creating a bilingual, evidence-focused newsletter, Graphy is attempting to differentiate itself through transparency and educational depth, a pattern that mirrors how early-stage medical device companies build credibility before scaling commercial sales.

From a practical standpoint, the newsletter's success will depend on whether Graphy can maintain consistent, high-quality content that genuinely addresses clinical pain points rather than devolving into product promotion. For dental professionals evaluating SMA-based treatment, this newsletter offers a direct line to the company's clinical data and technical support resources, which could lower the barrier to trial adoption. Graphy's next challenge is converting newsletter readership into clinical case submissions and, ultimately, into recurring material and service revenue from dental practices worldwide.